Skip to main content

Table 3 Comparison of SARS-CoV-2 NTAb produced with different SARS-CoV-2 vaccines and immunization schedules

From: Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world

SARS-CoV-2 vaccine

(an interval of two doses)

1 M

2 M

3 M

 

Median

SR

Median

SR

Median

SR

BBIBP-CorV (4 weeks)

70.49 (n = 10)

100%

78.43 (n = 11)

91%

29.17 (n = 15)

80%

BBIBP-CorV (8 weeks)

73.97 (n = 6)

100%

38.21 (n = 30)

87%

29.85 (n = 13)

77%

CoronaVac (4 weeks)

109.31 (n = 14)

100%

79.4 (n = 23)

96%

/

/

CoronaVac (8 weeks)

299.7 (n = 14)

100%

82.92 (n = 20)

100%

/

/

X2

8.977

/

12.344

/

/

/

P

0.03*

/

0.006*

/

0.235

/

  1. SR represents seropositive rate; X2 represents the test statistic for Kruskal–Wallis test; P < 0.05 represents there was significant difference